AML 12 - Acute myeloid leukaemia Adults (modified)

Not Applicable

Completed

• Conditions: eukaemia; Cancer; Acute myeloid leukaemia

• Registration Number: ISRCTN17833622
• Lead Sponsor: Medical Research Council (MRC) (UK)

Brief Summary

2001 results in http://www.ncbi.nlm.nih.gov/pubmed/11535508 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/16076872 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/19965647 2013 results in http://www.ncbi.nlm.nih.gov/pubmed/23439754 2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24855211 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29025912 (added 25/07/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2000-10-25
• Study Completion: 2001-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

1. Acute myeloid leukaemia (AML) (any type of de novo or secondary AML, including acute promyelocytic leukemia [APL])
2. Suitable for intensive therapy
3. Normally under the age of 60 years (but older patients can be entered if considered suitable)
4. Informed consent given

Exclusion Criteria

1. Previous cytotoxic therapy for leukaemia
2. Concurrent active malignancy
3. Blast transformation of CML
4. Pregnant or lactating
5. Intensive chemotherapy not considered to be an appropriate treatment option
6. Patients with APL are not eligible for the ATRA randomisation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival; complete remission (CR) rates and reason for failure; duration of remission; toxicity; quality of life; supportive care requirements.

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration